These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 23540381)

  • 1. [Hepatotoxicity in patients treated with endothelin receptor antagonists: systematic review and meta-analysis of randomized clinical trials].
    Macías Saint-Gerons D; de la Fuente Honrubia C; Montero Corominas D; Catalá-López F
    Med Clin (Barc); 2014 Apr; 142(8):333-42. PubMed ID: 23540381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ambrisentan therapy in patients with pulmonary arterial hypertension who discontinued bosentan or sitaxsentan due to liver function test abnormalities.
    McGoon MD; Frost AE; Oudiz RJ; Badesch DB; Galie N; Olschewski H; McLaughlin VV; Gerber MJ; Dufton C; Despain DJ; Rubin LJ
    Chest; 2009 Jan; 135(1):122-129. PubMed ID: 18812445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension.
    Aversa M; Porter S; Granton J
    Drug Saf; 2015 May; 38(5):419-35. PubMed ID: 25792028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative assessment of efficacy and safety of ambrisentan and bosentan in patients with pulmonary arterial hypertension: A meta-analysis.
    Zhao Q; Guo N; Chen J; Parks D; Tian Z
    J Clin Pharm Ther; 2022 Feb; 47(2):146-156. PubMed ID: 34319626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endothelin receptor antagonism: role in the treatment of pulmonary arterial hypertension related to scleroderma.
    Kabunga P; Coghlan G
    Drugs; 2008; 68(12):1635-45. PubMed ID: 18681488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.
    Wei A; Gu Z; Li J; Liu X; Wu X; Han Y; Pu J
    J Am Heart Assoc; 2016 Oct; 5(11):. PubMed ID: 27912207
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Removing the FDA's Boxed Hepatotoxicity Warning and Liver Function Testing Requirement for Ambrisentan.
    Feldman WB; Mahesri M; Sarpatwari A; Huybrechts KF; Zhu Y; Hwang CS; Lii J; Lee SB; Kattinakere Sreedhara S; Toyserkani GA; Zhou EH; Zendel L; LaCivita C; Manzo C; Dal Pan GJ; Kesselheim AS; Bykov K
    JAMA Netw Open; 2024 Jul; 7(7):e2419873. PubMed ID: 39023895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic stability after transitioning between endothelin receptor antagonists in patients with pulmonary arterial hypertension.
    Fox B; Langleben D; Hirsch AM; Schlesinger RD; Eisenberg MJ; Joyal D; Blenkhorn F; Lesenko L
    Can J Cardiol; 2013 Jun; 29(6):672-7. PubMed ID: 22819360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Endothelin receptor antagonists in the new European guidelines on pulmonary hypertension].
    Montani D; Humbert M
    Rev Mal Respir; 2010 Feb; 27(2):103-5. PubMed ID: 20206056
    [No Abstract]   [Full Text] [Related]  

  • 10. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
    Steiner MK; Preston IR
    Vasc Health Risk Manag; 2008; 4(5):943-52. PubMed ID: 19183742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment of pulmonary arterial hypertension: endothelin-receptor antagonists].
    Hoeper MM
    Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S308-10. PubMed ID: 17139593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A review of STRIDE-2 and STRIDE-2X: the case for selective endothelin receptor blockade.
    Langleben D; Cacoub P
    Eur J Clin Invest; 2009 Jun; 39 Suppl 2():27-31. PubMed ID: 19335744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small-molecule endothelin receptor antagonists: a review of patenting activity across therapeutic areas.
    Mucke HA
    IDrugs; 2009 Jun; 12(6):366-75. PubMed ID: 19517317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oral therapies for the treatment of pulmonary arterial hypertension: a population-based cost-minimization analysis.
    Dranitsaris G; Mehta S
    Appl Health Econ Health Policy; 2009; 7(1):43-59. PubMed ID: 19558194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of ambrisentan in the management of pulmonary hypertension.
    Hrometz SL; Shields KM
    Ann Pharmacother; 2008 Nov; 42(11):1653-9. PubMed ID: 18957622
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ironic case of hepatic dysfunction following the global withdrawal of sitaxentan.
    Don GW; Joseph F; Celermajer DS; Corte TJ
    Intern Med J; 2012 Dec; 42(12):1351-4. PubMed ID: 23253000
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver toxicity of sitaxentan in pulmonary arterial hypertension.
    Galiè N; Hoeper MM; Simon J; Gibbs R; Simonneau G;
    Eur Heart J; 2011 Feb; 32(4):386-7. PubMed ID: 21416695
    [No Abstract]   [Full Text] [Related]  

  • 18. Endothelin receptor antagonists in pulmonary arterial hypertension.
    Dupuis J; Hoeper MM
    Eur Respir J; 2008 Feb; 31(2):407-15. PubMed ID: 18238950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin receptor antagonists as disease modifiers in systemic sclerosis.
    Shetty N; Derk CT
    Inflamm Allergy Drug Targets; 2011 Feb; 10(1):19-26. PubMed ID: 21184655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of endothelin receptors in the treatment of pulmonary arterial hypertension: does selectivity matter?
    Opitz CF; Ewert R; Kirch W; Pittrow D
    Eur Heart J; 2008 Aug; 29(16):1936-48. PubMed ID: 18562303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.